FASEB J. FASEB Summer Research Conferences
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH
 QUICK SEARCH:   [advanced]


     


This Article
Right arrow Full Text (Rapid PDF)
Right arrow All Versions of this Article:
fj.08-109355v1
22/10/3432    most recent
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Niederberger, E.
Right arrow Articles by Geisslinger, G.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Niederberger, E.
Right arrow Articles by Geisslinger, G.
Published online before print June 17, 2008 as doi: 10.1096/fj.08-109355.

The IKK-NF-{kappa}B pathway: a source for novel molecular drug targets in pain therapy?

Ellen Niederberger and Gerd Geisslinger

E-mail contact: e.niederberger@em.uni-frankfurt.de

Several studies indicate that the nuclear factor-kappa B (NF-{kappa}B) -activation cascade plays a crucial role not only in immune responses, inflammation, and apoptosis but also in the development and processing of pathological pain. Accordingly, a pharmacological intervention into this pathway may have antinociceptive effects and could provide novel treatment strategies for pain and inflammation. In this review we summarize the role of NF-{kappa}B in the nervous system, its impact on nociception, and several approaches that investigated the effects of various modulators of the classical I-{kappa}B-kinase-NF-{kappa}B signal transduction pathway in inflammatory nociception and neuropathic pain. The results indicate that NF-{kappa}B has an impact on nociceptive transmission and processing and that a number of substances that inhibit the NF-{kappa}B-activating cascade are capable of reducing the nociceptive response in different animal models. Therefore, a modulation of specific participants in the NF-{kappa}B signal transduction might exert a useful approach for the development of new painkillers.—Niederberger, E., Geisslinger, G. The IKK-NF-{kappa}B pathway: a source for novel molecular drug targets in pain therapy?







HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH
Copyright © 2008 by The Federation of American Societies for Experimental Biology.